
    
      The duration of treatment with fitusiran is 9 months. The estimated total time on study,
      inclusive of Screening, for each patient is up to 11 months for all patients who enroll in
      the extension study and patients in the on-demand arm who do not enroll in the extension
      study. The estimated total time on the study may be up to 17 months in fitusiran treatment
      arm patients who do not enroll in the extension study due to the requirement for an
      additional 6 months of follow-up monitoring for antithrombin levels.

      Patients who complete the study may be eligible for an open-label extension study LTE15174
      (NCT03754790)
    
  